10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Mouse Mapk13 Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP14444B

Specification

Mouse Mapk13 Antibody (C-term) - Product Information

Application	**WB,E**
Primary Accession	Q9Z1B7
Other Accession	Q9WTY9, O15264, Q3T0N5, NP_036080.2
Reactivity	**Human**
Predicted	**Bovine, Rat**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit IgG**
Calculated MW	**42072**
Antigen Region	**336-364**

Mouse Mapk13 Antibody (C-term) - Additional Information

Gene ID 26415

Other Names
Mitogen-activated protein kinase 13, MAP kinase 13, MAPK 13, Mitogen-activated protein kinase p38 delta, MAP kinase p38 delta, Stress-activated protein kinase 4, Mapk13, Serk4

Target/Specificity
This Mouse Mapk13 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 336-364 amino acids from the C-terminal region of mouse Mapk13.

Dilution
WB~~1:1000
E~~Use at an assay dependent concentration.

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
Mouse Mapk13 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

Mouse Mapk13 Antibody (C-term) - Protein Information

Name Mapk13

Synonyms Serk4

Function Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK13 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as pro-inflammatory cytokines or physical stress leading to direct activation of transcription factors such as ELK1 and ATF2. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. MAPK13 is one of the less studied p38 MAPK isoforms. Some of the targets are downstream kinases such as MAPKAPK2, which are activated through phosphorylation and further phosphorylate additional targets. Plays a role in the regulation of protein translation by phosphorylating and inactivating EEF2K. Involved in cytoskeletal remodeling through phosphorylation of MAPT and STMN1. Mediates UV irradiation induced up- regulation of the gene expression of CXCL14. Plays an important role in the regulation of epidermal keratinocyte differentiation, apoptosis and skin tumor development. Phosphorylates the transcriptional activator MYB in response to stress which leads to rapid MYB degradation via a proteasome-dependent pathway. MAPK13 also phosphorylates and down- regulates PRKD1 during regulation of insulin secretion in pancreatic beta cells.

Mouse Mapk13 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Mouse Mapk13 Antibody (C-term) - Images



Western blot analysis of Mapk13 (arrow) using rabbit polyclonal Mouse Mapk13 Antibody (C-term) (Cat. #AP14444b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the Mapk13 gene.

Mouse Mapk13 Antibody (C-term) - Background

Mapk13 responds to activation by environmental stress and pro-inflammatory cytokines by

phosphorylating downstream targets. Plays a role in the regulation of protein translation by phosphorylating and inactivating EEF2K (By similarity).

Mouse Mapk13 Antibody (C-term) - References

Chakraborty, S., et al. Differentiation 78 (2-3), 143-150 (2009) :
Schindler, E.M., et al. Cancer Res. 69(11):4648-4655(2009)
Sumara, G., et al. Cell 136(2):235-248(2009)
Ruiz-Bonilla, V., et al. Cell Cycle 7(14):2208-2214(2008)
Liu, Y., et al. Dev. Biol. 314(1):224-235(2008)